We've all heard that imitation is the "sincerest form of flattery" … but why mess with the original (which has only gotten better over time)? Make film coating simple with the Opadry family of products!
关于我们
Through a commitment to innovation, quality and collaboration, we ensure our customers' products go from concept to commercialization, quickly and easily. We promise to deliver excellence in every product, every process and every interaction we have. At Colorcon, our science-based approach to product development drives our innovation. Our people-centric approach to customers and partners elevates it all. Learn more at www.colorcon.com.
- 网站
-
https://www.colorcon.com
卡乐康的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Harleysville,PA
- 类型
- 私人持股
- 创立
- 1961
- 领域
- Film Coating、Controlled Release Polymers、Multiparticulate Dosage Forms、Taste-Masking、Oral Dosage Formulation、Tablet Design、Pharmaceutical、Nutritional、Dietary Supplements、Functional Packaging、Controlled Release、Modified Release、Specialty Excipients和Controlled Atmosphere Packaging
地点
-
主要
275 Ruth Road
US,PA,Harleysville,19438
卡乐康员工
动态
-
In the world of controlled drug release, precision is everything. Our latest blog explores Push-Pull Osmotic Pump (PPOP) technology, a game-changer that: ?? Delivers drugs at a consistent rate ?? Overcomes solubility challenges ?? Enhances efficacy & safety Whether you're in pharmaceutical R&D or exploring next-generation drug formulations, our latest blog is must-read. ??https://hubs.li/Q03bnpMH0
-
-
Did you know that our new website has more than 125 educational articles on it?! Easy to filter and find exactly what you’re looking for, our library features trending topics around pharmaceuticals, dietary supplements, regulatory and more. Check out our Education & Insights today! https://hubs.li/Q0369-PS0
-
Innovation from the Inside Out. From core to coating to packaging, our goal is to safeguard your medications and ensure efficacy and reliability throughout their shelf life. Visit our new website to learn more. https://hubs.li/Q035FQbC0